I have just listened to the speech by Dr Jean-Francois DELFRAISSY, Director of the French National Agency for Research on AIDS and Viral Hepatitis (ANRS in the French acronym). My impressions:
1. Cure for HBV will be on the plan of ANRS
2. Some HCV resources will be channeled to HBV research
3. Budget for HCV will be reduced, HBV budget will increase
New interferons and immunomodulators
Jake Liang (USA)
There is one bad news: IFN lambda is inferior to IFN alpha in treating HBeAg+ patients. This is from a presentation by Dr Jake Liang, MD. However Dr Liang is more hopeful about GS9620.